Research programme: kinase inhibitors - GenentechAlternative Names: Kinase inhibitors research programme - Genentech
Latest Information Update: 25 Aug 2009
At a glance
- Originator Genentech
- Class Small molecules
- Mechanism of Action Phosphotransferase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 25 Aug 2009 Discontinued - Preclinical for Cancer in USA (unspecified route)
- 15 Jan 2007 Amphora Discovery Corporation sells its entire oncology research programme to Genentech
- 05 May 2005 Data presented at the 96th Annual Meeting of the American Association for Cancer Research (AACR-2005) have been added to the Cancer pharmacodynamics section